Search Results

CNNC & CIR Co-sponsors Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project Launched Simultaneously

Recently, the Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and the Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project were launched simultaneously at Ganzhou Cancer Hospital. An expert panel from the Nuclear Medicine Branch of the Chinese Medical Association, along with representatives from CNNC & CIR and Atom High-Tech, visited the hospital for research and exchange. More than 200 medical staff from medical institutions at various levels across Jiangxi Province attended the event. The launch ceremony was moderated by Yang Chuansheng, Director of the Nuclear Medicine Department at Ganzhou Cancer Hospital. Fu Wei, Deputy Director of the Ganzhou Municipal Health Commission; Wang Jing, Chair of the Nuclear Medicine Branch of the Chinese Medical Association; and Huang Xingwei, Party Secretary of Ganzhou Cancer Hospital, attended and delivered speeches. Wang Jing stated that nuclear medicine plays a vital supporting role in the precise diagnosis and treatment of major diseases such as cancer, and that promoting the standardized development of regional nuclear medicine at the city and county levels is conducive to channeling high-quality medical resources to the grassroots and enhancing primary healthcare service capabilities.

2026-08-06

UT-ORNL Recruits Radiopharmaceutical Scientist to Advance Integrated Cancer Diagnosis and Treatment

The University of Tennessee and Oak Ridge National Laboratory jointly announced that Dr. Carolyn Anderson has been appointed to the UT-ORNL Governor's Chair in Nuclear Medicine: Radiopharmaceutical Therapy. Anderson officially assumed the position on August 1, serving concurrently as a professor in the Department of Nuclear Engineering at the University of Tennessee, Knoxville, and as a researcher in the Isotope Science and Enrichment Directorate at Oak Ridge National Laboratory. She is an internationally renowned pioneer in the field of radiopharmaceutical science, having worked at institutions such as the University of Washington, the University of Pittsburgh, and the University of Missouri. Dr. Anderson's research focuses on developing compounds that can identify cancer earlier, assess treatment efficacy, and deliver radiation directly to tumors...

2026-08-04

DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical

DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.

2026-08-04

US FDA Approves Pluvicto Expanded Indication for Treatment of PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

On July 31, 2026, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer. This disease is commonly referred to as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on results from the Phase III PSMAddition trial. The study showed that compared with standard of care alone, namely ARPI combined with androgen deprivation therapy (ADT), Pluvicto plus standard of care reduced the risk of disease progression or death by...

2026-08-03

Santa Casa Hospital in Ceará, Brazil, Introduces New Linear Accelerator for Cancer Treatment

Santa Casa de Sobral Hospital in northern Ceará, Brazil, has introduced a new linear accelerator to strengthen cancer treatment for patients in the northern region. The hospital received a new linear accelerator for radiotherapy of cancer patients. After completing the installation, training, and licensing processes, this new technology is expected to double the institution's radiotherapy capacity, increasing from the current 600 patients per month to approximately 1,200 new patients. This equipment, the Halcyon linear accelerator, is considered the latest technology in radiotherapy and is the second unit of its kind installed in Ceará. The device is capable of providing faster, more precise, and safer treatment for various types of cancer...

2026-08-01

Kangbuk Samsung Hospital in South Korea Validates Precision of New-Generation Surface-Guided Radiation Therapy System

The research team from the Department of Radiation Oncology at Kangbuk Samsung Hospital in South Korea announced on July 31 that they have completed validation of the geometric accuracy and respiratory tracking performance of a new-generation surface-guided radiation therapy system. The research findings have been published in the latest issue of the international academic journal *Radiation Physics and Chemistry*. In breast cancer radiotherapy, the deep inspiration breath-hold technique is commonly used in clinical practice to reduce radiation exposure to the heart and lungs. Traditional procedures typically require tattoo marks or drawn guide lines on the patient's skin surface, along with wearing sensors to monitor respiratory motion, which somewhat compromises treatment convenience and patient comfort. The new-generation surface-guided radiation therapy system validated in this study utilizes 3D stereoscopic cameras and thermal imaging technology...

2026-08-02

Russian State Expert Review Authority Approves Design Changes for Ufa Radionuclide Therapy Center

Russia approves design changes for the Ufa Radionuclide Therapy Center, which will employ the latest technologies and equipment. The new center, located in the Republic of Bashkortostan, is expected to become a significant force in the local fight against cancer. With a floor area exceeding 6,000 square meters, the facility is a G-shaped three-story building with a basement. Its internal framework uses monolithic reinforced concrete to ensure stability and safety. The project's design strictly adheres to medical technology standards, aiming to create a modern and innovative treatment institution. At the core of the center is the radionuclide therapy department, which includes 24-hour inpatient wards, featuring a radionuclide supply area, a 20-bed "active" ward, and common areas. Additionally, it includes service and administrative zones to support the center's daily operations...

2026-08-01

TerraPower Isotopes to Donate Actinium-225 via Oncidium Foundation to Support Cancer Treatment Accessibility

TerraPower Isotopes (TPI), a subsidiary of U.S. nuclear innovation company TerraPower, announced on July 29 that it will coordinate the donation of the rare medical isotope actinium-225 (Ac-225) through the Oncidium Foundation to support economically disadvantaged cancer patients in accessing targeted radionuclide therapy. The Oncidium Foundation is a non-profit organization dedicated to promoting global access to targeted radionuclide cancer treatments. Its RLT-Connect program aims to help financially challenged patients access relevant therapies, reducing treatment disparities caused by geographic and economic conditions. This donation also marks TPI's entry into Oncidium's collaborative ecosystem of radioisotope suppliers, medical practitioners...

2026-07-30

Moffitt Cancer Center Activates Proton Therapy Center in Florida, USA

Moffitt Cancer Center recently held a ribbon-cutting ceremony, announcing the official opening of the Richard M. Schultz Family Foundation Proton Center at the Moffitt Speros Outpatient Center. Located in the Speros Global R&D Park in Pasco County, Florida, it is recognized as the first proton therapy center in the Tampa Bay area. Moffitt Cancer Center stated that the activation of the proton therapy center will provide local patients with more precise radiotherapy options. Built in collaboration with IBA, a particle accelerator technology company, the center will use proton therapy to deliver targeted radiation to tumors, improving tumor targeting accuracy while minimizing impact on surrounding healthy tissues. According to reports, the...

2026-07-30